(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
|
|
- ゆき しばもと
- 5 years ago
- Views:
Transcription
1
2 (1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA) (2) Draize (1) Ames in vitro in vivo (1) (2)...138
3 2-AA 9-AC ALP EMS DNCB ENNG OTC LD 50 NF 20-MC CPA MNPCE MCH MCHC PCE S.D. S.E N- -N - -N- ( ) 50% Micronucleated Polychromatic Erythrocytes Mean Corpuscular Hemoglobin Mean Corpuscular Hemoglobin Concentration Polychromatic Erythrocytes ( ) ( ) (+)-(S)-4-[1-(2,3-dimethylphenyl)ethyl]-1 H-imidazole monohydrochloride JAN dexmedetomidine hydrochloride (DEX) INN dexmedetomidine (R)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-i midazole
4 -1 (g/kg/) (g/kg/) : 5 mg/kg mg/kg : 10 mg/kg : 5 mg/kg mg/kg : 5 mg/kg : 2 mg/kg mg/kg : >2 mg/kg GLP ( ) -1 ( ) -2-3 ( ) -4-5 ( ) : < : <10 ( ) : < : <10 ( ) 10 6 Seg (2 ) ( ) ( ) Seg < ( ) Seg ( ) 8 16 ( ) g/kg/infusion ( ) ( ) ( ) g/kg/infusion 1.0 mg/animal -13 (6 ) ( ) 50g/animal -14 (10 ) ( ) 106
5 51500 g/plate ( ) Ames Test g/plate ( ) g/ml ( ) GLP ( ) g/ml S9 mix g/ml -18 ( ) in vitro g/ml -19 S9 mix g/ml ( ) g/kg ( ) NMRI 5.0 mg/kg ( ) -1 in vivo CD-1-21 mg/kg ( ) g/mL -22 g/ml ( ) g/mL in vitro -23 g/ml ( ) g/kg/ : 400 : 400 g/kg/ ( ) mg/kg 2 mg/kg 1 mg/kg g/kg/ 10g/kg/ g/kg/ 250g/kg/ 10g/kg/ 107
6 18g/kg/ 54g/kg/ 6g/kg/ 200g/kg/ 20g/kg/ 96g/kg/ 96g/kg/ 8g/kg/ 2g/kg/ ( ) Ames 5 mg/kg NMRI GLP CD-1 GLP 5 mg/kg L 28 PR 400 g/kg/ 108
7 0.120 mg/kg mg/kg 10 5 mg/kg NMRI 30 g mg/kg 5 5 mg/kg 5 mg/kg : mg/kg 10 mg/kg : 1 20 mg/kg : 1 SD mg/kg 5 5 mg/kg 5 5 mg/kg 5 mg/kg : 4 10 mg/kg : 5 20 mg/kg : 5 5 mg/kg : 4 10 mg/kg : 4 20 mg/kg : 5 109
8 mg/kg 14 ( -3) 2.0 mg/kg 1 1 ( ) mg/kg 2.0 mg/kg mg/kg 2.0 mg/kg mg/kg 2.0 mg/kg 1015kg mg/kg 0.1mL/kg mg/kg 1.0mg/kg 2.0mg/kg ( ) () ( ) ( ) () ( ) ( ) ( ) 2 mg/kg 110
9 1 10 SD g/kg/ g/kg/ 160g/kg/ 40g/kg/ g/kg/ 160g/kg/ 160g/kg/ MCH MCHC 10 g/kg/ 40g/kg/ ALP 160g/kg/ PT PTT 40g/kg/ 1) 40g/kg/ 160g/kg/ ALP ALP ALP 2 2) 160g/kg/ 40g/kg/ 3)-5) 111
10 10g/kg/ 10 /kg/ SD g 150 g 1 ml/kg (g/kg/) RBC Hb Ht Ht MCH MCHC Na + ALP ALP K +, Mg +, Na + ph ph ph ( ) ( ) ( ( ) ) <10g/kg/ Bonferonni t 1) Kaheinen, P.: Research Report , Farmos Group Ltd., Research Center 2) Hirsimaki, P. et al: Research Report , Farmos Group Ltd., Research Center 3) Kamibayashi, T. et al:anesthesiology 93: (2000) 4) Bloor, B.C. et al: Anesthesiology 77: (1992) 5) Schmeling W.T. et al: Anesthesiology 75: (1991) 112
11 g/ g/kg/ 250g/kg/ 50g/kg/ 50g/kg/ 250g/kg/ 10 ( ) 250g/kg/ g/kg/ OTC( ) 250g/kg/ GPT OTC GPT 1) 2),3) 50g/kg/ PAS (Intracytoplasmic eosinophilic inclusion bodies) 250g/kg/ 1 PAS 4)-7) 113
12 10g/kg/ 10g/kg/ kg kg 0.25 ml/kg (g/kg/) OTC OTC GPT ph ph * 10g/kg/ * OTC(Ornithine Transcarbamylase) 1) Amacher, D.E. et al: Food Chem Toxcol 36: (1998) 2) Sanhouri, A.A. et al: Br Vet. J. 146: (1990) 3) Yannai, S. et al: Arch Toxicol 54: (1983) 4) Ghadially, F.N.: Fourth Ed., Boston: Butterworth-Heinemann, pp , (1997) 5) Wills, E.J.: Ultrastructural Pathology 16: (1992) 6) Biava, C. et al: Am J Pathol 46: (1965) 7) Murti, G.S. et al: Am J Vet Res 26:63-67 (1965) 114
13 24 SD g/kg/ g/kg/ 54 / 18g/kg/ 18g/kg/ 6 g/kg/ 18 54g/kg/ 18g/kg/ 20 18g/kg/ 54g/kg/ 2 1), 2) 54g/kg/ g/kg/ 2 3) F1 18g/kg/ (F0) 18g/kg/ 6g/kg/ 54g/kg/ (F1) 18g/kg/ 6g/kg/ 1)Magness, R.R. et al : Am. J. Obstet. Gynecol , )Eisenach, J.C. et al : Am. J. Obstet. Gynecol. 160(2) , )Akatuka, K. et al : J. Toxicol. Sci.(Suppl 2)
14 ) SD 6~7 210 g 10~ g 1 ml/kg g/kg/ (%) 2) 100 (24/24) 91.7 (22/24) 100 (24/24) 100 (24/24) (%) 2) 100 (24/24) 81.8 (18/22) 95.8 (23/24) 95.8 (23/24) ,3,4) ,3,4) (%) ,2,4) (%) ,2,4) ,2,4) ,3,4) ( ) (g) 3,4) ** *** (100 ) (79 ) (77 ) (97 ) (%) 100 (12/12) 100 (8/8) 100 (13/13) 91.7 (11/12) () 4) , , , ** *** (%) (%) * *** (g) 4) *** *** (%) 90 (9/10) 100 (9/9) 100 (13/13) 92.3 (12/13) 1,3, (%) 1,3,4) F 2 4 (%) 2) (g) 4) g/kg/ 54g/kg/ 6g/kg/ (1) 1 2) Fisher 3)Bonferonni t 4) S.D. * p<0.05 ** p<0.01 *** p<
15 25 SD g/kg/ g/ / 200 g/kg/ 20g/kg/ 200g/kg/ g/kg/ 200g/kg/ g/kg/ Seg 2 20g/kg/ 2g/kg/ 200g/kg/ 20g/kg/ 200g/kg/ 20g/kg/ 117
16 SD 3 ( ) g 1 ml/kg (g/kg/) ) 1,3,4) ,3,4) ,3,4) (% *** 2,3,4) ** 2,3,4) ) )1) *** (g) 1,4) *** (g) 1,4) *** ( ) 1) g/kg/ 20g/kg/ 20g/kg/ 1) Bonferroni t 2) 2 Fisher 3) * p< 0.05,** p< 0.01, *** p< ) S.D. 118
17 12 Himalayan g/kg/ g/kg/ 60 24g/kg/ g/kg/ 24g/kg/ g/kg/ g/kg/ 6g/kg/ 6g/kg/ 96g/kg/ 96g/kg/ Himalayan kg ml/kg g/kg (g/kg/) ) 1,3,4) ,3,4) () 2) % ,3,4) ) hr hr ) (g) 1,4) (g) 1,4) ( ) 2) (%) <6g/kg/ 96g/kg/ 96g/kg/ 1)t 2)Fisher 3)1 4) S.D. 119
18 1 22 SD g/kg/ Seg Seg 2g/kg/ 32g/kg/ 8g/kg/ 8g/kg/ 32g/kg/ 16g/kg/ 4 32 g/kg/ 8g/kg/ 7 (16 ) 32g/kg/ 2 32g/kg/ 20 32g/kg/ 8g/kg/ 2g/kg/ 120
19 SD ~240 g 1 ml/kg g/kg/ ) (%) 100 (22/22) 95.5 (21/22) 100 (22/22) 100 (21/21) 4) 1,3,7) (%) ,3,7) (%) (g) ( ) ) (%) 100 (21/21) 100 (21/21) 100 (21/21) 100 (21/21) (%) 95.2 (20/21) 100 (21/21) 100 (21/21) 90.5 (19/21) 1,3,7) ,3,7) ,3,7) ,3,7) ,3,7) F 2 (g) 7) (g) 7) g/kg/ 2g/kg/ 2g/kg/ 1) t 2) 2 Fisher 3) 1 4) 1 5) 6) 7) S.D. * p<0.05 ** p<0.01 *** p<
20 g/kg 416g/kg g/kg 0.25g/kg 4g/kg 8g/kg 4g/kg 8 16g/kg SD 116g/kg g/kg SD 8 16g/kg/ 4 mg/kg/ (168 ) 2 ml/kg/ mg/kg ) g/kg 122
21 p0.05, (Mann-Whitney U ) g/kg ( -10) hr 5hr p0.05 (Dunnett ) 123
22 No. 1hr 5hr S702 S705 S777 2mL/kg/infusion S786 S789 S793 L776 L779 L780 L790 8g/kg/infusion L791 L796 H701 H769 H782 16g/kg/infusion H783 H784 H785 P700 P767 P770 4mg/kg/infusion P792 P794 P797 : : ++ :
23 6 ( kg) 3 mg/kg mg/kg g/kg (16 24 mg/kg) 2 Seevers (A) (B) (1) (%)100 AB A 3 1 No. (%) 0.5 ml/kg 0.25 ml/kg g/kg g/kg mg/kg 24 mg/kg ) ) Seevers, M.H. : J. Pharmacol. Exp. Ther. 56, ,
24 4 ( kg) 10 / g/kg/ 30 / g/kg g/kg 30 / g/kg/ g/kg g/kg * (1 )** (2 )** (g/kg) 125 or or 1.0 No or 3 2 or * 3 ** 1 No g/kg (2 ) 0.25g/kg No
25 PCA Draize Hartley ( g 6 /) 2 ml(t 0 : ) 1.0 mg/2 ml/animal (T 1 : ) 1.0 mg/2 ml/animal (T 2 )1 3 2 (6 ) ml (T 0 T 1 T 2 T 3 T 4 T 5 ) 45 T 3 T mg /ml/animal T mg/ml/animal 0.5% (T 4 ) (T 3 ) (T 5 ) T 0 T 1 1) 2) PCA / s.c. T 3 (0.1 mg/animal) 5) i.v. 06 (1.0 mg/animal) 3) s.c. T 4 (1.0 mg/animal) 6) i.v. 66 T 2 (1.0 mg/animal) 4) s.c. T 5 (0.1 mg/animal) 5) i.v. 06 1) 3 2 (6 ) 2) PCA 1/16 1/64 1/ ) (0.5 mg/ml)2ml # 4) (0.5 mg/ml)2 ml # 5) (0.1 mg/ml)1 ml 6) (1.0 mg/ml)1 ml # 127
26 Hartley ( g 6~10 /) (T 0 : ) 0.05(w/v)DNCB(T 1 : ) 0.05 # (T 2 ) 1 3 (10 ) (1 0.1 ml/animal ml/animal) 2 T DNCB T 0 T ml DNCB (T 1 ) (T 0 T 2 ) ( -14) / No. T 0 T 1 T 2 / / DNCB /DNCB / (24 48 ) (24 48 ) 4 0/6 3/6 0/10 # 128
27 Ames in vitro in vivo TA1535 TA1537 T1538 TA98 TA g/ 5000g/ g/ g/ g/plate 1) 5 5g/plate 6 ( -15) 1500g/ g/ WP2uvrA g/ g/ 7 ( -16) 11000g/plate 1) OECD Guideline for testing of chemicals No. 471: Bacterial reverse mutation test 129
28 / TA1535 TA1537 TA1538 TA98 TA100 (g/ ) S-9mix (-) S-9mix (+) ENNG IL IL IL IL IL IL AC 80.0 X X NF AA IL IL IL IL S.D. N=3 ENNG N- -N - -N- 9-AC 9- NF 2-2AA 2- IL X 130
29 WP2uvrA / (g/ ) S-9mix (-) S-9mix (+) ENNG AA ENNG N- -N - -N- S.D. N=3 2AA 2-131
30 L5178Y TK+/-TK-/- L5178Y S-9mix TK % 200g/mL 10150g/mL S-9mix 2 S-9mix S-9mix 40g/mL 20200g /ml S-9mix 40g/mL 22237/10 6 cells 1) ( -17) (g/ml) () 1 2 () S-9mix () S-9mix () DMSO EMS *** *** DMSO * MC *** *** EMS 20-MC cell *p0.05, ***p ) Mitchell I.deG. et al: Mutagenesis 5: (1990) 132
31 18 32 S-9 mix % 3 S-9mix (1 300g/mL 2 350g/mL 32 ) % ( -18) S-9mix S-9mix S-9mix(-)EMS( ) S-9mix(+)CPA( ) (g/ml) S-9mix g *** 18 () (%) g *** 1 + (g/ml) S-9mix g * 20.0*** () (%) g * 20.5*** + (g/ml) S-9mix g *** 18 () (%) g *** + (g/ml) S-9mix g *** () (%) g *** 2 + (g/ml) S-9mix g *** 32 () (%) g *** + (g/ml) S-9mix g * 37.5*** () (%) g * 38.0*** (g) (+g) ***p0.001, *p
32 S-9mix -18 S-9mix 1 168g/ml 488g/ml g/ml g/ml 3 19 C B1-19 S-9mix 3 1 S-9mix S-9mix (-) C S-9mix (+) B1 S-9mix () S-9mix () 19 S-9mix () 2 3 S-9mix () 100 * p0.05 (g/ml) (%) * + (g/ml) (%) * + (g/ml) (%) * + (g/ml) * (%) + 134
33 NMRI g/kg PCE/NCE 2000 PCE PCE MNPCE g/kg -20 PCE/NCE MNPCE 250g /kg NMRI 5 mg/kg GLP -1 GLP NMRI g ( 24 ) 40( /kg) PCE/NCE MNPCE (%) PCE/NCE ( /kg) 250( /kg) 40(mg/kg) ** ** ** MNPCE (%) MNPCE(Micronucleated Polychromatic Erytrocytes) MNPCE(%)=MNPCE /PCE 100 **p0.01 1) O brien, H. et al: Br J Haematol 51: (1982) 2) Asanami, S. et al.: Mutation Res. 393: (1997)
34 CD mg/kg % 1ml PCE/NEC MNPCE (%) 50 mg/kg PCE/NECMNPCE (%) PCE/NEC MNPCE (%) CD (m /kg) 2.5(m /kg) 5.0(m /kg) 50(mg/kg) PCE/NCE * MNPCE (%) ** 24 PCE/NCE MNPCE (%) PCE/NCE * MNPCE (%) ** 48 PCE/NCE MNPCE (%) MNPCE(Micronucleated Polychromatic Erytrocytes) MNPCE(%)=MNPCE /PCE 100 *p0.05, **p
35 5 SD g/mL( 0.1mL) 5 20 mg/ml g/mL g/mL 1000g/mL 1 10 SD 400g 1 5 ( g/ ml 0.1mL 5 20mg/mL 0.1mL 0.1mL (g/ml) 20mg/mL
36 g/mL in vitro ( ) ( ) 545 nm g/mL 3000g/mL 100% ( ng/mL*) *: DEX W97-249W97-245W97-246W99-302W J-DEX mL 100L nm (g/ml) (%) g/kg/ 10000g/kg g/kg 2000g/kg 1 PR g/kg g/kg g/kg 10000g/kg 400g/kg/ 138
37 kg g (1 :3 :3 ) 400, 2000, 10000g/kg/ g/kg/ 3 2 (g/kg/) ) 2) PR 1) 2) 2) 400g/kg/ 1) 2) 139
参考資料5 農薬評価書 メタアルデヒド(食品安全委員会資料)
1 3 3 4 5. 6 1. 6 2. 6 3. 6 4. 6 5. 6 6. 6 7. 6. 7 1. 7 2. 8 (1) 8 (2) 9 (3) 9 (4) 10 (5) 10 3. 11 (1) 11 (2) 11 (3) 11 (4) 12 4. 12 (1) 12 (2) 12 (3) 13 5. 13 6. 13 7. 14 8. 15 9. 16 10. 16 (1) 90 16-1
More informationCTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11
More informationESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm
1 186 186 (1) - 192 (2) (ISAintrinsic sympathomimetic activity) 199 (3) ( MSAmembrane stabilizing activity) 2 (4) 21 (5) 212 (6) 216 (7) 219 (8) 224 (9) (ASL-8123) - 229 (1) d-esl l-esl - 231 2 235 235
More information1999年3月作成(新様式第1版)
200622 19989 871313 1mL4mg JAN oxybuprocaine hydrochloridejan 2002621 20037 4 19667 1 FAX 2005 10 29607 05 1 63 () 103 2 3 49 111 4 Drug Safety Update 1. -------------------------------------1 2. -----------------------1
More information20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine
More information(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
More information取扱説明書 [F-08D]
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 a bc d a b c d 17 a b cd e a b c d e 18 19 20 21 22 a c b d 23 24 a b c a b c d e f g a b j k l m n o p q r s t u v h i c d e w 25 d e f g h i j k l m n o p q r s
More information040202PC用.doc
15 48 15 8 25 15 1321 15 8 25 0825002 15 8 25 6 8 15 2 18 15 6 27 2 15 3 13 28 35 (1) 51 198 7 (2) 3 6 1 100g (1) 1 (1) 1 2 1 astaxanthin;3,3 -dihydroxy-, -carotene-4,4 -dione (2) 1 2 C40H52O4 596.86 97.0
More informationPSCHG000.PS
a b c a ac bc ab bc a b c a c a b bc a b c a ac bc ab bc a b c a ac bc ab bc a b c a ac bc ab bc de df d d d d df d d d d d d d a a b c a b b a b c a b c b a a a a b a b a
More information10 2 2 10 6.5 78 1 65 / 30 / - 2 -
- 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9
More informationグリセオール注インタビューフォーム
2006 8 3 873999 871319 IF 1998 9 FAX 1 200mL 300mL 500mL 20g 30g 50g 10g 15g 25g 1.8g 2.7g 4.5g 0.9W/V 200mL500mL 1979 3 13 2004 7 9 1979 5 15 2006 8 300mL 1979 3 13 2004 7 9 1982 11 1 IF 1 MR 63 IF 10
More informationuntitled
1 2 1 2002 8 1 2003 11 1 152 2003 11 2 21 53 2003 12 24 4 54 2004 3 22 55 2004 4 9 56 2004 4 15 41 2004 4 15 2004 5 12 2004 5 19 2004 5 20 5 2004 12 16 58 2 2005 1 25 2005 8 23 5962 2005 8 26 2005 9 1
More information200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
More information- 108 -
3-107- - 108 - 3.1 3.1.1 3.1.2 3.1.2.1 5 LD50 LC50 ATE 3.1.1 1 2 3 4 5 (mg kg ) 5 50 300 2000 5000 a (mg kg ) 50 200 1000 2000 a (ppm) 100 500 2500 5000 a b mg 0.5 2.0 10 20 a b c d 0.05 0.5 1.0 5 (mg
More informationuntitled
2001 4 26 2003 5 22 2004 7 12 2004 7 15 54 2004 7 21 14 2004 9 16 62 IUPAC4--2--N,N --5-p --1-2 17.07 mg/kg / 100 0.17 mg/kg /ADI cyazofamidiso IUPAC 4--2--N,N- -5-p --1-4-chloro-2-cyano-N,N -dimethyl-5-p
More informationCAS H 3 C C CH 2 C 9 H tert d = hpa
1 200140 35 CAS 98839 1335-2- H 3 C C CH 2 C 9 H 10 118.18 1 99 4-tert- 1. 2-23.2 2 163164 2 54 574 3 0.96.6 20 d 4 0.9082 2 4.07 = 1 2.5 hpa 1.9 mmhg20 2 4 log Pow3.48 3.44 m/z 118, 1.0 103 0.58 91 0.21
More information取扱説明書 [F-12C]
F-12C 11.7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 a bc b c d d a 15 a b cd e a b c d e 16 17 18 de a b 19 c d 20 a b a b c a d e k l m e b c d f g h i j p q r c d e f g h i j n o s 21 k l m n o p q r s a X
More informationuntitled
ORYZA OIL & FAT CHEMICAL CO., LTD. WHITE JELLY FUNGUS EXTRACT -P () Ver. 1.3SJ Ver. 1.3SJ 1. 3000 ph 1 Ver. 1.3SJ 1. 1 2. 3 2-1. 2-2. 2-3. 2-4. SOD 3. 7 3-1. in vitro 3-2. in vivo 3-3. in vivo 3-4. in
More information387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
More informationエクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF
2005 1 872646 IF 1998 9 1g 3mg(0.3%) Deprodone Propionate 2003227 200374 1997415( ) 1998316( ) F A X 2003 7 1992 3 17 1997 10 9 1992 5 22 1997 12 19 IF 2005 4 IF 1. MR 63 2 IF 10 3 IF 2. IF IF IF 3. IF
More information125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
More information50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
More informationエディロールカプセルインタビューフォーム
2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/
More information3 光毒性第三者評価報告書100924改
21 5 13 22 5 17 1 2 in vivo 24 in vivo 9 6 6 GLP 1 b 4 Acridine BMDM 4-t-butyl-4-methoxydibenzoylmethane CHD Chlorhexidine Bithionol CHD Bithionol in vivo in vivo b in vivo 70% b 5 in vitro 3T3-NRU 4 9
More information,977 t 157,977 t mg l mg l BOD 9398 % OH = cm 3 / sec 11 = cm 3 / sec OH = /
1 9625 2219 CAS 75569 1, 2-1, 2- H 2 C CH CH 3 C 3 H 6 O 58.08 1 99 % 1. 2 2, 3-112.13 2, 3 34.23-37 449 2.8-37 % 2 d 0 4 0.859 4 d 20 0.8304 2 2, 4 2.00 = 1 53.33 kpa 400 mmhg18 59.33 kpa 445 mmhg20 5
More information1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET i BALF ii CVF i ii BALF i ii iii BALF i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4)
1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET ibalf ii CVF i iibalf i ii iiibalf i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4) ET CVF (5) (6) 3) (1)in vitro 2. 1)ONO-5046Na (1) (2) (3) (4)
More information23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213
More informationuntitled
20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20
More information48 * *2
374-1- 17 2 1 1 B A C A C 48 *2 49-2- 2 176 176 *2 -3- B A A B B C A B A C 1 B C B C 2 B C 94 2 B C 3 1 6 2 8 1 177 C B C C C A D A A B A 7 B C C A 3 C A 187 187 C B 10 AC 187-4- 10 C C B B B B A B 2 BC
More informationケイセントラ_製品情報概要_H1-4_収載_新発売
DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1
More information2009年133巻3号3月号.indb
Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine
More informationuntitled
ver. 3.3JT EVENING PRIMROSE EXTRACT 1 - PMS 1 2 1 4 Oenothera laciniata Oenothera striata Oenothera biennis Oenothera erythrosepala - 2 80 60 40 20 0 1. 2 3 PGGPAC 2. 3 4 ESR3.5 10 5 /g 4 3 1 Helicobacter
More information140 120 100 80 60 40 20 0 115 107 102 99 95 97 95 97 98 100 64 72 37 60 50 53 50 36 32 18 H18 H19 H20 H21 H22 H23 H24 H25 H26 H27 1 100 () 80 60 40 20 0 1 19 16 10 11 6 8 9 5 10 35 76 83 73 68 46 44 H11
More informationC033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
More informationMicrosoft Word - fiñfiÅ’«.doc
H N S O O H N H 3 C 3 µ µ µ µ GLP Douglas, W.W. (1980): Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In: Goodman and Gilman s The Pharmacological Basis of Therapeutics, 6th
More informationエコリシン点眼液/眼軟膏インタビューフォーム
2011 11 4 871319 1mL 5mg 5mg15 1g 5mg 5mg15 JAN JAN Erythromycin LactobionateJAN Colistin Sodium MethanesulfonateJAN 1970 3 31 1970 8 1 1970 7 20 TEL0120-921-839 06-6321-7056 9 17 https://www.santen.co.jp/medical/admin/a300.jsp
More information報告書
1 2 3 4 5 6 7 or 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 2.65 2.45 2.31 2.30 2.29 1.95 1.79 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 60 55 60 75 25 23 6064 65 60 1015
More information温泉の化学 1
H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970
More informationContents 4 06 IP2 41 Thermo Scientific Nalgene Nalgene
Nalgene & Packaging plastic Bottles & Vials Contents 4 06 IP2 41 Thermo Scientific Nalgene 5 07 42 8 08 43 9 09 45 11 10 46 Nalgene 12 11 50 13 12 53 01 20 13 61 02 28 14 64 03 33 15 66 04 37 16 / 67 05
More information総合薬学講座 生物統計の基礎
2013 10 22 ( ) 2013 10 22 1 / 40 p.682 1. 2. 3 2 t Mann Whitney U ). 4 χ 2. 5. 6 Dunnett Tukey. 7. 8 Kaplan Meier.. U. ( ) 2013 10 22 2 / 40 1 93 ( 20 ) 230. a t b c χ 2 d 1.0 +1.0 e, b ( ) e ( ) ( ) 2013
More informationuntitled
COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5
More information合併後の交付税について
(1) (2) 1 0.9 0.7 0.5 0.3 0.1 2 3 (1) (a), 4 (b) (a), (c) (a) 0.9 0.7 0.5 0.3 0.1 (b) (d),(e) (f) (g) (h) (a) (i) (g) (h) (j) (i) 5 (2) 6 (3) (A) (B) (A)+(B) n 1,000 1,000 2,000 n+1 970 970 1,940 3.0%
More information福岡大学人文論叢47-3
679 pp. 1 680 2 681 pp. 3 682 4 683 5 684 pp. 6 685 7 686 8 687 9 688 pp. b 10 689 11 690 12 691 13 692 pp. 14 693 15 694 a b 16 695 a b 17 696 a 18 697 B 19 698 A B B B A B B A A 20 699 pp. 21 700 pp.
More information秋田県2012-初校.indd
http://www.kairyudo.co.jp/ 2012 AKITA 2 3 4 10 15 1 2 3 2 cm 110.7 111.6 109.8 110.6 5 kg 19.0 19.5 18.6 19.1 cm 61.9 62.2 61.5 61.6 cm 116.7 117.8 115.8 116.8 6 kg 21.4 22.5 21.0 21.9 cm 64.9 65.4 64.5
More information本文/一般演題_吉田
184 quality of lifeqol mmhg Hb gdl CA Uml Niveau Hb Hb gdl RCC CT MRI T 185 CT A B MRI A:T B:T Douglas red spot S ml RCC 186 A B mg CAUml S MRI A B 187 188 S mg Sampson JA. Intestinal adenomas of endometriosis
More informationuntitled
ORYZA CERAMIDE -PTPCDP8TP20CD -WSPWSP8 -LL0.8 -PCPC8PC20 -WSPCWSPC8 -LCLC0.8 Ver.13.0HS ORYZA CERAMIDE Ver.13.0HS 1. 2. 20 NMR 4 ( 1) 1 Ver.13.0HS HO CH 2 OH O O OH OH OH C CH CH H 2 NH C O R C H C H (CH
More information1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
More informationver5.1 HS 1. ALPHA LIPOIC ACID () S S COOH HS 1. α - SH COOH - ( 1) CoA -( 2)- - --P80 (--WSP8-L1-WSPC8 -LC1) - 1
ORYZA OIL & FAT CHEMICAL CO., LTD. ALPHA LIPOIC ACID --P () --P80 () --WSP8 () --L1 () --PC () --PC80 () --WSPC8 () --LC1 () ver. 5.1HS ver5.1 HS 1. ALPHA LIPOIC ACID 16 3 31 0331009 - () 19 5 24 0524001
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More information2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
More informationuntitled
35 36 1) 120.07m 2 2 1 LDK 2 2 5 2 3.1.1 ab 3.1.1 3.1.2 910 2730 910 4095 1820 3 8 2F 6.5 6.5 650 650 910 3640 910 910 5460 1820 450 1137.5 1820 1820 1137.5 450 910 3640 2957.5 2957.5 2 910 2730 1820 1820
More informationSynagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
More information国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
More information,309 t 22,069 t 7,240 t µg/l µg/l < ,431-70, , , mg/l m
1 20019 1527 CAS 1317368 1230 PbO 223.20 1 99 1. 2 888 2 9.53 0.017 g/l 20 3 3 2 2. 10 29,309 t 22,069 t 7,240 t 4 1 3. 1 2 3.5 6 1 µg/l 9.1-24 2 µg/l < 43 6 27,431-70,000 4.5-1,300 13.4-17 31.7 0.48-3,459
More informationボトックス注用
2018 5 21 2017 1220 5 8 7 1 2 2 9 50 100 22100AMX00488 22100AMX00489 2009 9 2009 9 2009 2 1997 4 2016 6 2018 5 1989 12 1A 2 1 2 3 2 4 5) 1 100 1 2 3 4 A 1 50 50 0 45mg 0 25mg 100 100 0 9mg 0 5mg A 1 4mL
More informationt 492 t mg/l 30 mg/l BOD 95 OH = cm 3 / sec 25 8 OH /cm 3 12 = ph ph
2-1 200169 2740 CAS 110-49-6 1103 2- O H 3 C C O CH 2 CH 2 O CH 3 C 5 H 10 O 3 118.13 200168 2-1 99 2-1. 2 2, 3-65 2, 3 144145 45 o.c. 3 392 3 1.512.3 d19 1.009 2 4.07 = 1 30 Pa 0.23 mmhg20 2 4 log Pow0.10
More information3 光毒性第三者評価報告書100924改
評価報告書 酵母光生育阻害試験と赤血球光溶血性試験の 組み合わせによる光毒性試験代替法 平成 22 年 1 月 国立医薬品食品衛生研究所 15 11 25 18 12 6 15 11 25 1 2 3 4 21 5 13 22 5 17 1 2 in vivo 24 in vivo 9 6 6 GLP 1 b 4 Acridine BMDM 4-t-butyl-4-methoxydibenzoylmethane
More information橡Taro11-報告書0.PDF
Research Center RC 2001 5-1- RC RC NHK -2- -3- 00/12/16 RC 01/01/07 RC 01/01/21 1 13 01/02/11 2 9 01/02/10 01/02/14 01/02/19 01/02/25 3 7 01/03/10 4 8 01/03/23 5 8 01/04/29 2001/01/07-4- -5- RC 1990 RC
More information2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1
Mg-LPSO 2566 2016 3 2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1 1,.,,., 1 C 8, 2 A 9.., Zn,Y,.
More informationuntitled
1% 1 mg 1 mg 2 CTD 6 Section 2.6.1 Introduction 2.6.1 H 1 descarboethoxyloratadinesch 34117 7.9 SCH 34117 2.6.1-1 O OC 2 H 5 Cl N N JAN Loratadine (JANINN) ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]
More information橡99-24_00 アリルアルコール.PDF
1 9924 2260 CAS 107186 H 2 C CH CH 2 OH 2- -1- C 3 H 6 O 58.08 1 99 1. 2, 3 3, 4, 5-129 96-97 2 21c.c. 24o.c. 2 6, 7 378 6, 7 2.5-18 d 20 4 0.8540 2, 5 2.00 = 1 2.7 kpa 20 mmhg204.3 kpa 32 mmhg30 4 log
More information取扱説明書 [F-02F]
F-02F 4. 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 a b c d a b c d a b cd 9 e a b c d e 20 2 22 ab a b 23 a b 24 c d e 25 26 o a b c p q r s t u v w d h i j k l e f g d m n a b c d e f g h i j k l m n x 27 o
More information1. 4cm 16 cm 4cm 20cm 18 cm L λ(x)=ax [kg/m] A x 4cm A 4cm 12 cm h h Y 0 a G 0.38h a b x r(x) x y = 1 h 0.38h G b h X x r(x) 1 S(x) = πr(x) 2 a,b, h,π
. 4cm 6 cm 4cm cm 8 cm λ()=a [kg/m] A 4cm A 4cm cm h h Y a G.38h a b () y = h.38h G b h X () S() = π() a,b, h,π V = ρ M = ρv G = M h S() 3 d a,b, h 4 G = 5 h a b a b = 6 ω() s v m θ() m v () θ() ω() dθ()
More information2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
More informationCRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
More information九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
More information/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %)
/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) (10 2 %) 0.32 0.55 0.37 0.55 95 165 115 185 (10 2 %) 0.75 (10 2 %) 0.15 (10 2 %) 0.10 10 2 % 0.10 10 2 % 0.15 10 2 % 0.10 Bands(10 2 %) 0.10 (10 9 75
More information% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
More information(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
More information瀬田唐橋景観検討について
3 3 12,174 /12hr 1,110 /12hr 3,066 /12hr 172.0m 51.75m 23.5+5@25.0+23.5m 3@17.25m 14.0m 15.0m 5 6 2009 12 3 2010 2 25 6/22 8/24 10/18 11/16 1/13 1797 16 15 15 13 6 (S49) 54 7 23-2 24 54 50
More informationSBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
More informationまえがき
JAAS0012006 1 -------------------------------------------------------------------------------------------------------- 1 2 --------------------------------------------------------------------------------------------------------
More informationJuntendo Medical Journal
The hair growth effect of minoxidil Susumu OTOMO, Ph. D. Key words : minoxidil, minoxidil sulfate, hair growth, K+-channel opener, male pattern baldness Dept. of Pharmacology, Research Center Taisho Pharmaceutical
More informationuntitled
CoQ10 CoQ10 CoQ10 CoQ10 CoQ10 (A CoQ10 CoQ10 B CoQ10 CoQ10 C CoQ10 CoQ10 CoQ10 QOL CoQ10 QOL CoQ10 CoQ10 CoQ10 CoQ10 14 還元型 CoQ10 の摂取はインフルエンザウイルス感染に対する予防効果を示す CoQ1050CoQ10 CoQ1080CoQ10 Åberg et al., Arch
More informationuntitled
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -
More informationアクテムラインタビューフォーム
2009 2 6 876399 IF 1998 9 FAX 80mg 1 4mL 80mg 200mg 1 10mL200mg 400mg 1 20mL400mg JAN TocilizumabGenetical RecombinationJAN 200mg 80400mg 2007 9 10 2008 4 16 2007 12 21 2008 6 13 2005 6 13 2008 6 13 2009
More information繁殖性に及ぼす影響
5. 2 1. (DEP) 1) DEP 2) 3) 4) DEP 0 600 3000 15000 ppm(0 43 210 1083 mg/kg/day 0 54 261 1336 mg/kg/day ) 24 Crj:CD(SD) IGS 2 DEP 15000 ppm F0 0-21 F1 F0 F1 DEP F1 F1 15000 ppm 15000 ppm F0 F1 F0 F0 P-450
More information用法 用量 発作性夜間ヘモグロビン尿症における溶血抑制 mg mg mg mg kg 30kg 40kg 20kg 30kg 10kg 20kg 5kg 10kg 1900mg mg mg mg
C EculizumabGenetical Recombination AMX 警告 1 2 禁忌 ( 次の患者には投与しないこと ) 1 2 組成 性状 ml mg mg mg mg mg ph ph mgml 効能 効果 発作性夜間ヘモグロビン尿症における溶血抑制 < 効能 効果に関連する使用上の注意 > 共通 1C5 C5b-9 b 発作性夜間ヘモグロビン尿症における溶血抑制 1 2 3 4
More information3 4
2 3 4 5 6 Contents 117 9 30 10 00 10 30 12 00 13 30 15 30 1700 15 00 9 30 10 00 Contents 118 11 30 13 00 14 30 15 00 1630 7 22 36 8 7 Report MC 2000 Report MC 2000 10 9 12 11 14 13 16 15 18 17 20 19 22
More informationDCHP
2. 2 1. 1) 2) 2 Crj:CD(SD)IGS SPF 0 240 1200 6000 ppm 2 F0 10 F0 10 F1 21 F1 3 10 F1 3 10 F2 21 0 240 1200 6000 ppm 1 F0 0 15.88 79.57 401.8 mg/kg/day F0 0 20.80 104.19 510.7 mg/kg/day F1 0 17.84 89.89
More informationuntitled
2007 12 1 871146 IF 1998 9 350mg 250mg 100mg 10mg 10mg Sodium Salicylate Sulpyrine Hydrate Caffeine Hydrate Allobarbital Procaine Hydrochloride 2007 8 31 2007 12 21 1955 2 FAX TEL FAX IF 2007 12 6 IF 1
More information1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF
2003 7 3 872189 873919 IF 1998 9 PROBEAN CAP. 1 250mg Polyenephosphatidylcholine 1998 9 16 1999 7 9 1999 7 FAX IF 2003 7 1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR
More informationuntitled
RYZA IL & FAT CHEMICAL C., LTD. SAKURA EXTRACT Ver.1.4MK Ver. 1.4MK 1) 1300 1929 1 Ver. 1.4MK Sakura 1-caffeoyl---D-glucopyranoside quercetin 3---D-glucopyranoside 1) :, 4, 11-22 (1995). 2 Ver. 1.4MK 3
More information; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
More informationuntitled
ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504
More information2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
More information案内(最終2).indd
1 2 3 4 5 6 7 8 9 Y01a K01a Q01a T01a N01a S01a Y02b - Y04b K02a Q02a T02a N02a S02a Y05b - Y07b K03a Q03a T03a N03a S03a A01r Y10a Y11a K04a K05a Q04a Q05a T04b - T06b T08a N04a N05a S04a S05a Y12b -
More information1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
More information